Cite
HARVARD Citation
Glatt, S. et al. (2018). Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Annals of the rheumatic diseases. 77 (4), pp. 523-532. [Online].